STOCK TITAN

Marinus Pharmaceuticals to Present at Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Marinus Pharmaceuticals (Nasdaq: MRNS) announced its participation in two key investor conferences this September. The company will present at the Baird 2022 Global Healthcare Conference in New York on September 13 at 2:35 p.m. ET, and at the H.C. Wainwright 24th Annual Global Investment Conference on September 14 at 12:00 p.m. ET. Interested parties can access event links on the company’s Investors & Media page. A replay of the presentations will be available shortly after each event.

Positive
  • None.
Negative
  • None.

RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will present and participate in the following investor conferences in September.

  • Baird 2022 Global Healthcare Conference (New York, NY) on Tuesday, September 13 at 2:35 p.m. ET. This event is closed to conference participants only.
  • H.C. Wainwright 24th Annual Global Investment Conference (New York, NY) on Wednesday, September 14 at 12:00 p.m. ET.

Links to each event can be accessed on the Investors & Media page of Marinus’ website at ir.marinuspharma.com/events-and-presentations. A replay of the webcasts will be available approximately two hours after the completion of the events and will be archived for up to 90 days.

About Marinus Pharmaceuticals

Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company’s commercial product, ZTALMY® (ganaxolone) oral suspension CV, has been approved by the U.S. FDA for the treatment of seizures associated with CDKL5 deficiency disorder in patients two years of age and older. The potential of ganaxolone is also being studied in other seizure disorders, including in Phase 3 trials in tuberous sclerosis complex and refractory status epilepticus. Ganaxolone is a neuroactive steroid GABAA receptor modulator that acts on a well-characterized target in the brain known to have anti-seizure effects. It is being developed in IV and oral formulations to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings. For more information visit www.marinuspharma.com.

Company

Sasha Damouni Ellis

Vice President, Corporate Affairs & Investor Relations

Marinus Pharmaceuticals, Inc.

sdamouni@marinuspharma.com

Source: Marinus Pharmaceuticals, Inc.

FAQ

What conferences will Marinus Pharmaceuticals participate in September 2022?

Marinus Pharmaceuticals will participate in the Baird 2022 Global Healthcare Conference on September 13, 2022, and the H.C. Wainwright 24th Annual Global Investment Conference on September 14, 2022.

What date and time will Marinus Pharmaceuticals present at the Baird Conference?

Marinus Pharmaceuticals will present at the Baird 2022 Global Healthcare Conference on September 13, 2022, at 2:35 p.m. ET.

When is the H.C. Wainwright Conference for Marinus Pharmaceuticals?

The H.C. Wainwright 24th Annual Global Investment Conference for Marinus Pharmaceuticals is scheduled for September 14, 2022, at 12:00 p.m. ET.

Where can I find the links to Marinus Pharmaceuticals' investor conference presentations?

Links to Marinus Pharmaceuticals' investor conference presentations can be found on their Investors & Media page.

Will Marinus Pharmaceuticals provide a replay of the conference presentations?

Yes, Marinus Pharmaceuticals will provide a replay of the conference presentations approximately two hours after completion, available for up to 90 days.

Marinus Pharmaceuticals, Inc

NASDAQ:MRNS

MRNS Rankings

MRNS Latest News

MRNS Stock Data

17.32M
49.03M
10.94%
83.04%
10.28%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
RADNOR